Glenmark Pharmaceuticals Inc., USA — a subsidiary of Glenmark Pharmaceuticals Limited — has announced plans to introduce Ropivacaine Hydrochloride Injection USP in November 2025, marking an important expansion of its injectable portfolio. The launch reinforces Glenmark’s commitment to delivering high-quality and affordable therapeutic alternatives in the U.S. pharmaceutical market.
The Ropivacaine Hydrochloride Injection USP will be available in three dosage strengths: 40 mg (20 mL), 150 mg (30 mL), and 200 mg (20 mL). These single-dose vials are bioequivalent and therapeutically equivalent to the reference listed drug Naropin® Injection, manufactured by Fresenius Kabi USA, LLC.
The introduction of Glenmark’s formulation is expected to increase competition in the local anesthetic injection market, currently dominated by Naropin®. According to IQVIA® sales data for the 12-month period ending August 2025, Naropin® Injection achieved annual sales of approximately $20.9 million.
Marc Kikuchi, President & Business Head, North America, Glenmark Pharmaceuticals Inc., USA, said:
“We are pleased to announce the launch of Ropivacaine Hydrochloride Injection USP. This launch represents another important addition to Glenmark's expanding injectable portfolio and reinforces our dedication to bring quality and affordable alternatives to market for patients in need.”
The launch is expected to strengthen Glenmark’s presence in the anesthetics segment and further enhance its growing range of complex generics in the U.S. market.
Also Read